KOZARICH JOHN W 4
4 · LIGAND PHARMACEUTICALS INC · Filed Apr 2, 2026
Research Summary
AI-generated summary of this filing
Ligand (LGND) Director John W. Kozarich Sells Shares
What Happened
- John W. Kozarich, a director of Ligand Pharmaceuticals (LGND), sold a total of 467 shares in multiple open-market transactions on April 1, 2026. The individual lots reported were: 146 shares @ $199.97 ($29,196); 40 shares @ $201.24 ($8,049); 79 shares @ $202.42 ($15,991); 43 shares @ $202.91 ($8,725); and 159 shares @ $204.26 ($32,478), for aggregate proceeds of approximately $94,439. These were sales (not purchases) and therefore are not a bullish signal; they were executed pursuant to a pre-existing trading plan.
Key Details
- Transaction date: 2026-04-01 (Form 4 filed 2026-04-02 — appears to be timely).
- Prices: reported as weighted-average prices by lot; per footnotes the sale-price ranges were: $199.6900–$200.3150, $201.0050–$201.4650, $202.0750–$202.6400, $202.8550–$203.6550, and $204.0050–$204.5400. The reporter offers to provide a per-price breakdown on request.
- Shares sold: 467 total; Aggregate proceeds ≈ $94,439.
- Shares owned after the transaction: not stated in the provided filing excerpt.
- Notable footnotes: F1 — sales were made under a written Rule 10b5-1 trading plan adopted March 7, 2025; F2–F6 — prices are weighted averages with ranges and an undertaking to disclose per-price details if requested.
- Filing timeliness: Form filed the next day (2026-04-02), which is within the usual two-business-day Form 4 deadline.
Context
- Because these sales were executed under a Rule 10b5-1 plan (a pre-scheduled trading arrangement), they may reflect a pre-set liquidity plan rather than a reaction to recent company developments. Sales are common for insiders for diversification or tax/planning reasons; purchases are generally more informative about insider conviction.
Insider Transaction Report
Form 4
KOZARICH JOHN W
Director
Transactions
- Sale
Common Stock
[F1][F2]2026-04-01$199.97/sh−146$29,196→ 42,574 total - Sale
Common Stock
[F1][F3]2026-04-01$201.24/sh−40$8,049→ 42,534 total - Sale
Common Stock
[F1][F4]2026-04-01$202.42/sh−79$15,991→ 42,455 total - Sale
Common Stock
[F1][F5]2026-04-01$202.91/sh−43$8,725→ 42,412 total - Sale
Common Stock
[F1][F6]2026-04-01$204.26/sh−159$32,478→ 42,253 total
Footnotes (6)
- [F1]The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1.
- [F2]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $199.6900 to $200.3150. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $201.0050 to $201.4650. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $202.0750 to $202.6400. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $202.8550 to $203.6550. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F6]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $204.0050 to $204.5400. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Signature
By: /s/Andrew Reardon, Attorney-in-Fact For John W. Kozarich|2026-04-02